Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFOX + FOLFIRI + panitumumab
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
FOLFOX + FOLFIRI + panitumumab is a combination treatment regimen evaluated in the CAIRO5 phase 3 clinical trial, conducted by the Dutch Colorectal Cancer Group (DCCG). This regimen is designed for patients with initially unresectable, liver-only colorectal metastases, specifically those with left-sided tumors and RAS/BRAF wild-type status. It consists of a doublet chemotherapy backbone—either FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil) or FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil)—administered alongside panitumumab (Vectibix). Panitumumab is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting the signaling pathways that drive tumor proliferation. The goal of this intensive induction therapy is to downsize liver metastases to enable surgical resection. Results from the CAIRO5 trial indicated that while the addition of panitumumab increased response rates compared to bevacizumab, it did not improve progression-free survival and was associated with higher toxicity.
- Other names
- FOLFOX/FOLFIRI + panitumumabDoublet chemotherapy + panitumumabFOLFOX + panitumumabFOLFIRI + panitumumab
02
Targets
Beyond the preview
Go deeper on FOLFOX + FOLFIRI + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFOX + FOLFIRI + panitumumab.